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Introduction (Nella A. Greggio, 
Vincenzo De Sanctis)
The short stature term describes a subject’s height that is 
significantly below the average for age, sex and racial group. 
The large number of clinical conditions associated with short 
stature can make the task of identifying a specific diagnosis 
particularly challenging (1).
The human growth depends from a complex interaction 
among nutritional, environmental and hormonal factors and by 
a large number of different genes. One of these genes, short 
stature homeobox (SHOX), is believed to play a major role in 
growth (2, 3). 
The mechanism by which SHOX, a homeodomain transcription 
factor, regulates linear growth and why deficiency of this 
factor results in short stature is not completely understood. 
The protein is expressed during pre- and postnatal skeletal 
development and regulates aspects of chondrocyte 
differentiation in the growth plate (4-6). 
It appears that two functional copies of this gene are 
required for attainment of normal stature since it has 
been established that haploinsufficiency for the gene is 
associated with a wide spectrum of conditions. All conditions 
are characterized by growth failure such as Leri-Weill 
dyschondrosteosis (LWD), Turner syndrome (TS), short stature 
with subtle auxological and radiological findings and the so 
called “idiopathic short stature” (short stature with no specific 
findings other than growth failure-ISS).
Finally homozygosity for the SHOX deficiency is associated 
with the more severe phenotype of Langer mesomelic 
dysplasia (LMD) (2, 3).
Aims and methods (Vincenzo De 
Sanctis, Nella A. Greggio)
This document has been prepared by a multidisciplinary 
team (paediatric endocrinologists, paediatrician, radiologist, 
geneticist and epidemiologist) in order to focus on the 
investigation of children with suspected SHOX- deficiency for 
an early identification and a correct diagnostic workup of this 
genetic disorder. All this to give an aid to clinicians working in 
primary and secondary health care services. 
In the development of recommendations the Committee 
reviewed more than 180 original articles and selected reviews 
on SHOX- gene and its mutation, ISS, short stature with and 
without dysmorphic features and Madelung’s deformity.
All Members of the Panel participated in the preparation of 
manuscript.
The document does not intend to substitute physician judgement 
with respect to particular patients or special clinical situation.
The SHOX Gene and Its Mutations 
(Nella A. Greggio, Maurizio Clementi)
The SHOX gene is present in two identical copies in all 
individuals and is a located in the pseudoautosomal region 1 
(PAR 1) on the distal end of X and Y chromosomes at Xp22.3 
and Yp11.3. SHOX also spans approximately 40 kb in the PAR1 
and consists of seven exons. The PAR1 region escapes from 
X-inactivation process and recombines during male meiosis. 
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The SHOX Gene and The Short Stature
 Two copies of the SHOX gene are normally expressed in males 
as well in females (3). 
SHOX encodes two differentially spliced mRNA, SHOXa and 
SHOXb. The two isoforms are differently expressed in tissues. 
SHOXa is expressed in skeletal muscle, placenta, pancreas 
and heart. SHOXb is a transcriptional modulator of SHOXa and 
is expressed in foetal kidney and skeletal muscle. In addition 
both are particularly expressed in bone marrow fibroblasts (3).
The SHOX gene encodes a homeodomain transcription factor 
expressed during early foetal life in developing skeletal tissue of 
the radius and ulna, the tibia and distal femur, and the first and 
second pharyngeal arches (3). SHOX functions as a repressor for 
growth plate fusion and skeletal maturation in the distal limbs, 
so that SHOX haploinsufficiency results in premature growth plate 
fusion and relatively advanced skeletal maturation in such regions 
(3). The protein is specifically expressed in the growth plate in 
hypertrophic chondrocytes undergoing apoptosis and appears to 
play an important role in regulating chondrocyte differentiation 
and proliferation (5, 6). 
Recently, a strong positive effect of SHOX on the expression 
of the fibroblast growth factor receptor gene FGFR3, a 
well known factor for limb development, has been recently 
reported by Decker et al (6). These findings offers a possible 
explanation for the phenotypes seen in patients with FGFR3 
(e.g. achondroplasia) and SHOX defects (e.g. LWD).
Insufficient amount or abnormal function of SHOX protein 
due to a mutation in one copy of SHOX compromises normal 
growth. Mutations include deletions, missense and nonsense 
mutations in both genes or in its regulatory elements (7-10).
Deletions are the main cause of SHOX mutation (70% are 
interstitial deletions and 30% are terminal). Mutations in 
the regions of SHOX are less frequent than deletions, with a 
prevalence of exons 3 and 4 coding for the homeodomains .The 
majority of point mutations are missense mutations (9, www.
shox.uni-hd.de).
SHOX- related haploinsufficiency disorders (SHOX-D) are 
inherited in a pseudoautosomal dominant manner. Absence 
or malfunction of one copy of the two SHOX genes suffices to 
cause the phenotype. The mutated copy can be derived from 
either the father or the mother. SHOX deficiency frequently 
occurs in several members of a family. No phenotypic 
differences have been noted between individuals with a 
deletion in SHOX and those with point mutation (8, 9). 
Prevalence of SHOX-D (Paola Facchin, 
Lorena Pisanello)
SHOX-D accounts for at least 50%-90% of patients with LWS 
and in almost 100% of TS subjects (11-14).
On the basis of a number of screening studies, SHOX-D 
appears to be a relatively frequent cause of short stature. A 
recent study conducted in 1534 ISS children without clear or 
significant or recognized body disproportion detected a SHOX 
mutation in 3%-5% of ISS children (2), the percentage increased 
to 22% when children with disproportionate short stature were 
included in the selection criteria (13).
Therefore, we can expect a population prevalence of SHOX-D 
at least of 1 in 2000, higher than that of TS, which occurs in 1 
in 2500 live female births and of growth hormone deficiency 
(1: 3.500) (11,14).
Molecular Genetic Testing and 
Diagnostic Implications of SHOX-D 
(Maurizio Clementi) 
Several techniques have been applied to identify these 
abundant deletions, including fluorescence in situ hybridization, 
microsatellite analysis, quantitative PCR (qPCR) with amplicons 
restricted to the SHOX gene and more recently multiplex ligation-
dependent probe amplification (MLPA) (9, 13-16). 
Essentially, laboratory diagnosis involves three steps.
At first chromosome analysis is performed to search for a 
deletion of the PAR1 pseudautosomal region. Second, using 
MLPA (multiplex ligation dependent probe amplification), 
presence / absence of the SHOX gene is tested. Third, 
provided no deletion of SHOX is found, the entire gene is 
sequenced. Sequencing detects alterations in the building 
blocks of the DNA (point mutations) (9). 
The deletion/point mutations ratio is 4:1 the sporadic/
familiar form ratio is 1: 2,5 (13). Of the 59 mutation reported 
in the literature, 41 have been detected in patients with LWD, 
10 in ISS, 5 in Langer syndrome and 3 were not correlated with 
a specific phenotype (3).
The SHOX mutations are spread across the entire coding 
region. In particular,
21 were located in exon 3 (44.7%), 9 mutations in exon 2 
(19.1%), 8 in exon 4 (17%), 5 in exon 6a (10.6%), 3 in exon 5 
(6.4%), 1 in intron 2 (2.1%) (3).
Prenatal diagnosis for pregnancies at increased risk 
is possible by analysis of DNA extracted from foetal cells 
obtained by amniocentesis usually performed at approximately 
15-18 weeks’ gestation or chorionic villus sampling at 
approximately ten to 12 weeks’ gestation. Both disease-
causing alleles of an affected family member must be 
identified before prenatal testing can be performed (17).
SHOX Deficiency Phenotype: Clinical 
Diagnosis (Nella A. Greggio, Lorenzo 
Iughetti, Franco Antoniazzi, Giorgio 
Tonini, Ilaria Tosetto, Elena Monti) 
Mutations or deletions of the SHOX gene are associated with 
a broad spectrum of phenotypic effects, even among affected 
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members of the same family, ranging from short stature 
without evident dysmorphic signs to profound mesomelic 
skeletal dysplasia, a form of short stature characterized by 
disproportionate shortening of the middle (mesial) segments 
of the upper and lower limbs (i.e. the forearms and lower legs) 
(8, 18-22). 
Clinical signs are more frequent and more severe in girls, 
probably because the SHOX(X) is more prone to be deleted 
compared to SHOX(Y) (13,14)
The LWD phenotype is highly variable with some patients 
being of normal height and showing no clinical signs of 
Madelung deformity. As far as stature concerned, usually they 
grow along the -2 SD growth curves before puberty, show a 
downward growth shift with puberty, reaching a final height 
approximately of 145 cm in females and 155 cm in males (3, 
13, 18-22).
It is likely that prepubertal growth is relatively well 
preserved because of dormant gonadal function, whereas 
pubertal growth is compromised because of gonadal oestrogens 
production that facilitate growth plate fusion (21,22).
The TS patients exhibit a complete or partial absence of 
one of the X chromosomes and among other clinical features, 
they present skeletal abnormalities such as short stature 
(95%), stature disproportion, neck webbing, lymphedema, 
high-arched palate, short metacarpals, scoliosis, Madelung 
deformity (7%), hearing difficulties, cardiac and renal 
anomalies, primary amenorrhea (1,23,24). The phenotype 
is variable; some females manifest only short stature or 
primary amenorrhea. The final adult height of women with 
Turner syndrome who have not received any growth-promoting 
therapy is reduced by approximately 20 cm or 3.0 SD below 
the mean (23, 24).
LMD is a rare homozygous or compound heterozygous form 
of SHOX-D (incidence of 1:1.000.000) and is characterized 
by extreme dwarfism, profound mesomelia, and severe limb 
deformity (3). 
In ISS subjects with SHOX haploinsufficiency the prenatal 
growth appears to be compromised. Postnatal growth is 
along the -2 SD growth curve throughout the growth period 
in absence of biochemical and hormonal alterations. The 
final height deficit is about 2 SD below the mean of normal 
population (3, 13, 18-22).
Finally SHOX haploinsufficiency is quite unlikely in patients 
with no evidence of Madelung deformity or mesomelia, 
especially in those with severe short stature (< 3 SD) 
accompanied by a reduced height velocity (21).
In summary a SHOX deficiency should be taken into 
consideration on the basis of a number of physical features, 
such as:
1. short stature
2. increased upper/lower segment ratio ( sitting height/
standing height)
3. reduction of ratio between arm SPAN / forearm length 
4. cubitus valgus (carrying angle)
5. Madelung wrist deformity 
6. bowing of forearms
7. short metacarpals/metatarsals 
8. apparent muscular hypertrophy 
9. increased body mass index (BMI)
10. high-arched palate, abnormal auricular development, 
micrognathia and short neck
A n a l y z i n g  t h e  l i t e r a t u r e  t h e r e  a r e  s e v e r a l 
possibilities for identifying patients candidate for SHOX-D 
analysis and below we have listed a series of scores that could be 
considered independently, on the basis of the above 
mentioned physical characteristics.
We have therefore taken into account as proposed by Munns 
et al (8), Rappold et al (2) and Binder et al (14 )which have 
suggested helpful parameters to individuate the most eligible 
candidates for the molecular analysis of the SHOX gene. 
For Munns (8) a candidate for SHOX deficiency investigation is 
a subject with:
1. Low birth weight and short stature through childhood
2. A final height consistently shorter than normal siblings 
3. A family history of short stature at least in one parent
Whilst Rappold (2) reported a scoring approach based on the 
evaluation of 3 anthropometric measurements:
1 .arm SPAN/height ratio <96.5% (2 points)
2. sitting height/standing height ratio > 55.5% (2 points)
3. BMI > 50th percentile (4 points)
 
Plus five clinical variables:
1. cubitus valgus (2 points)
2. short forearm (3 points)
3. bowing of forearm (3 points)
4. muscular hypertrophy (3 points)
5. dislocation of ulna ( or elbow) (5 points)
Importantly, the limit given in percentage by this score are 
only valid in school children (7).The graphs for normative 
assessment of SH/SH are available in : www.growth analyzer.org
The Rappold’s score was based on the data of 1,608 short 
individuals including 68 individuals with SHOX deficiency.(2) 
Testing for SHOX-D is recommended for subject with a score 
greater than 7 of a total possible score of 24. At a cut-off of 7 
points the positive predictive value is 19% (2). 
Finally, Binder et al. (14) defined as diagnostic criteria the 
integration of 3 parameters: leg length + arm span/sitting 
height. A ratio more than 1 SD below the mean for school age 
children is suggestive for SHOX-D (14).
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 Skeletal Abnormalities: Diagnostic 
Implications (Tiziana Toffolutti, Franco 
Antoniazzi) 
Several skeletal radiological abnormalities have been 
described in patients with SHOX defects. In particular , it is 
of practical importance to recognise early or mild signs of 
Madelung deformity on hand and wrist radiographs that are 
almost invariably obtained for the evaluation of bone age in 
children with short stature, such as : metaphyseal lucency 
and epiphyseal hypoplasia at the ulnar border of the distal 
radius, radial curvature ,decreased carpal angle, angulation 
of the distal radius and ulna, subluxation of the distal ulna , 
short fourth metacarpals, true shortening of the total length 
of the radius, exostosis at the distal ulnar border of the radius, 
lateral and dorsal curvature of the radius and exostosis at the 
distal ulnar border of the radius (3,21, 24 - 26).
Children with a severe degree of wrist deformity are 
significantly shorter than those with mild deformities.
When such findings are suspected, a radiograph of the distal 
limbs should be requested for curvature ,shortening and/or 
deformity of tibia (21).
It is important to note that (3, 4, 14, 24- 26):
1. Madelung deformity may not be apparent until mid- 
childhood and is usually preceded by radiological signs 
2. the presence of a clear radiological lucency (brightness) 
of the distal radius and the severe degree of triangulated 
of the distal radial epiphysis result in a poorer prognosis in 
comparison with individuals who have only mild radiological 
signs
3. the skeletal changes of dyschondrosteosis and are less 
common in males.
4. skeletal features tended to be more severe in females 
than in males and became more obvious after puberty .
Non-Skeletal Abnormalities
Up to now, SHOX expression has not detected in cardiac, 
renal or vascular organogenesis (17).
Treatment of Manifestations (Lorenzo 
Iughetti, Nella A. Greggio, Giorgio 
Tonini)
Short Stature
The molecular diagnosis of SHOX-D in children with ISS or 
LWD has therapeutic implications. Treatment with recombinant 
human growth hormone (rhGH) augments the growth of 
individuals with LWD and may improve final adult height (26). 
Untreated patients show a height loss from - 1.2 SDS at 11 
years to - 2.4 SDS at final height, whereas treated children 
improve their height from - 2.3 SDS at 11 years to -1.7SDS at 
final height ( + 0.6 SD) (26-29).
The concurrent use of rhGH and gonadotropin-releasing 
hormone agonist to delay pubertal onset in females with LWD 
may be of benefit when onset of puberty is early or Madelung 
deformity is present (30).
Bilateral Madelung deformity
Conservative management consists of wrist splints and 
supports during periods of increased discomfort and the use of 
ergonomic devices (17,31-33). 
Surgery have been attempted to decrease pain, improve 
cosmetics, and restore wrist function in patients with severe 
wrist deformity. 
The rationale for an early intervention is to alter the 
natural history of the deformity by excising the area of 
dyschondrosteosis in the distal radius, thus restoring growth in 
the distal radius (17, 34-38).
Conclusions (Vincenzo De Sanctis, 
Nella A. Greggio)
This document was intended to provide guidelines for the 
investigation of children with SHOX- related short stature for 
a correct diagnostic work - up to help clinicians in primary and 
secondary health care services. 
In fact the challenge for the paediatrician is to perform 
an early identification of short children who shows one or 
more abnormalities at physical examination, particularly 
dysmorphic features (39). For few syndromes diagnostic 
criteria have been developed (40, 41). A relatively frequent 
genetic disorder associated to short stature is SHOX-D (3).
Deletions or mutations of the SHOX gene have been reported in 
approximately 70% of patients with LWS and 3-22% of children 
with the clinical phenotype of ISS. Overall, the prevalence 
of SHOX-D (1:2000) appears to be higher of TS (1: 2500 live 
female births) and growth hormone deficiency (1: 3.500) (13).
The skeletal defects are present in a large phenotypic 
variation, according to the severity of expression and bone 
involvement, and tends to worsen with puberty. The SHOX 
gene is expressed neither in the axial skeleton development 
nor in the skull. 
The following recommendations were suggested by our 
multidisciplinary team:
(i) a careful family history, measurements of body proportions 
and detection of any dysmorphic features are important for 
the identification of a genetic disorder ,(ii)the presence of any 
combination of the following physical findings, such as reduced 
arm span/height ratio, increased sitting height/height ratio, 
above average BMI, Madelung deformity, cubitus valgus, short 
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or bowed forearm, dislocation of the ulna at the elbow, or 
the appearance of muscular hypertrophy, should prompt the 
clinician to obtain a molecular analysis of the SHOX region, 
(iii) it is of practical importance to recognise early or mild 
signs of Madelung deformity on hand and wrist radiographs 
that are almost invariably obtained for the evaluation of bone 
age in children with short stature, (iv) growth hormone, after 
stimulation test, is usually normal. However, treatment with 
rhGH may improve final adult height .The efficacy of treatment 
is similar to that observed in those treated for TS.
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